• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506.FK506 作用下原位肝移植术后排斥反应的发生率及治疗情况
Transplant Proc. 1991 Feb;23(1 Pt 2):928-30.
2
Experience with Orthoclone OKT3 monoclonal antibody in liver transplantation.Orthoclone OKT3单克隆抗体在肝移植中的应用经验。
Am J Kidney Dis. 1988 Feb;11(2):141-4. doi: 10.1016/s0272-6386(88)80199-9.
3
Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.在肾功能受损的肝移植受者中使用达利珠单抗作为初始免疫抑制治疗。
Liver Transpl. 2001 Mar;7(3):220-5. doi: 10.1053/jlts.2001.22455.
4
Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3?
Transplant Proc. 1993 Aug;25(4):2693-4.
5
Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.达利珠单抗诱导治疗、他克莫司、霉酚酸酯和类固醇作为原发性肾移植受者的免疫抑制方案。
Transplantation. 2002 Apr 15;73(7):1100-6. doi: 10.1097/00007890-200204150-00015.
6
Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.用于治疗肾移植受者急性排斥反应的多克隆抗体和单克隆抗体。
Cochrane Database Syst Rev. 2017 Jul 20;7(7):CD004756. doi: 10.1002/14651858.CD004756.pub4.
7
Increased risk of early rejection correlates with recovery of CD3 cell count after liver transplant in patients receiving OKT3 induction.在接受OKT3诱导治疗的肝移植患者中，早期排斥反应风险增加与肝移植后CD3细胞计数的恢复相关。
Transplantation. 1997 Oct 27;64(8):1214-6. doi: 10.1097/00007890-199710270-00026.
8
Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction.在无抗体诱导的原发性脑死亡供体肝移植和活体供肝移植中，静脉注射霉酚酸酯联合他克莫司及类固醇的潜在免疫学优势
Liver Transpl. 2008 Feb;14(2):202-9. doi: 10.1002/lt.21348.
9
Effect of OKT3 on survival and rate of retransplantation.OKT3对生存率及再次移植率的影响。
Transplant Proc. 1987 Aug;19(4 Suppl 3):61-2.
10
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.用于肾移植受者诱导治疗的多克隆抗体和单克隆抗体。
Cochrane Database Syst Rev. 2017 Jan 11;1(1):CD004759. doi: 10.1002/14651858.CD004759.pub2.

引用本文的文献

1
Prediction of Early Recurrence of Solitary Hepatocellular Carcinoma after Orthotopic Liver Transplantation.预测肝移植术后单发肝细胞癌的早期复发。
Sci Rep. 2019 Nov 1;9(1):15855. doi: 10.1038/s41598-019-52427-8.
2
Simple Risk Score for Prediction of Early Recurrence of Hepatocellular Carcinoma within the Milan Criteria after Orthotopic Liver Transplantation.米兰标准肝移植术后早期复发肝细胞癌的简单风险评分。
Sci Rep. 2017 Mar 9;7:44036. doi: 10.1038/srep44036.
3
Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years.肝移植术后使用他克莫司免疫抑制治疗的妊娠情况：单中心13年经验更新
Transplantation. 2003 Sep 15;76(5):827-32. doi: 10.1097/01.TP.0000084823.89528.89.
4
Pediatric liver transplantation in 808 consecutive children: 20-years experience from a single center.808例连续儿童的小儿肝移植：单中心20年经验
Transplant Proc. 2002 Aug;34(5):1955-7. doi: 10.1016/s0041-1345(02)03136-6.
5
Pediatric liver transplantation. A single center experience spanning 20 years.小儿肝移植。一个中心20年的经验。
Transplantation. 2002 Mar 27;73(6):941-7. doi: 10.1097/00007890-200203270-00020.
6
Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years.他克莫司能否为初次肝移植后的慢性排斥反应提供几乎完全的预防？1048例肝移植患者的风险及预后因素分析，平均随访6年。
Liver Transpl. 2001 Jul;7(7):623-30. doi: 10.1053/jlts.2001.25364.
7
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center.单中心4000例连续肝移植患者的长期生存情况。
Ann Surg. 2000 Oct;232(4):490-500. doi: 10.1097/00000658-200010000-00004.
8
Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation.他克莫司与环孢素在儿童肝移植中的长期比较评估。
Transplantation. 2000 Aug 27;70(4):617-25. doi: 10.1097/00007890-200008270-00015.
9
What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.关于在他克莫司免疫抑制下进行的原位肝移植，我们了解到了什么？对首批1000例患者的长期随访。
Ann Surg. 1999 Sep;230(3):441-8; discussion 448-9. doi: 10.1097/00000658-199909000-00016.
10
Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events.他克莫司治疗下的成人原位肝移植：超过90个月的实际随访生存情况及不良事件
Liver Transpl Surg. 1999 Mar;5(2):144-50. doi: 10.1002/lt.500050209.

本文引用的文献

1
IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION.FR 900506对人T淋巴细胞同种异体激活的体外免疫抑制作用。
Surg Res Commun. 1987;1:315-323.
2
FK 506 for liver, kidney, and pancreas transplantation.用于肝脏、肾脏和胰腺移植的FK 506。
Lancet. 1989 Oct 28;2(8670):1000-4. doi: 10.1016/s0140-6736(89)91014-3.
3
Renal transplantation in baboons under FK 506.在使用FK506的情况下狒狒的肾移植
Surgery. 1989 Aug;106(2):444-50; discussion 450-1.
4
Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction.FK506对犬、猴和狒狒同种异体移植物的免疫抑制作用：特别提及与其他药物的协同作用及耐受性诱导。
Surgery. 1988 Aug;104(2):239-49.
5
FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.FK-506，一种从链霉菌中分离出的新型免疫抑制剂。II. FK-506的体外免疫抑制作用。
J Antibiot (Tokyo). 1987 Sep;40(9):1256-65. doi: 10.7164/antibiotics.40.1256.
6
Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine.单独接受FK-506或与环孢素联合使用时大鼠的异位心脏移植
Transplant Proc. 1987 Oct;19(5 Suppl 6):71-5.
7
Infections after liver transplantation: risk factors and prevention.肝移植后的感染：危险因素与预防
Transplant Proc. 1991 Jun;23(3):1929-30.
8
Liver, kidney, and thoracic organ transplantation under FK 506.在使用FK506情况下的肝脏、肾脏及胸部器官移植。
Ann Surg. 1990 Sep;212(3):295-305; discussion 306-7. doi: 10.1097/00000658-199009000-00008.
9
Kidney transplantation under FK 506.在使用FK506的情况下进行肾脏移植。
JAMA. 1990 Jul 4;264(1):63-7.
10
FK 506 dosage in human organ transplantation.人体器官移植中FK506的剂量
Transplant Proc. 1990 Feb;22(1):23-4.

FK506 作用下原位肝移植术后排斥反应的发生率及治疗情况

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506.

作者信息

Jain A B, Fung J J, Todo S, Alessiani M, Takaya S, Abu-Elmagd K, Tzakis A, Starzl T E

机构信息

Department of Surgery, University of Pittsburgh, Pennsylvania.

出版信息

Transplant Proc. 1991 Feb;23(1 Pt 2):928-30.

PMID:1703354
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2967371/
Abstract

FK 506 therapy with low doses of steroids was adequate to control rejection in most liver recipients. Rejection episodes were readily reversed with single IV doses of methylprednisone or hydrocortisone. Short courses of OKT3 (3 to 5 days 5-10 mL) controlled severe rejections. The rate of retransplantation directly due to rejection was low (1.6%). There was a limited need for steroids either early or out to 6 to 12 months.

摘要

低剂量类固醇的FK 506疗法足以控制大多数肝移植受者的排斥反应。单次静脉注射甲基强的松龙或氢化可的松可迅速逆转排斥反应发作。短疗程的OKT3（3至5天，5 - 10毫升）可控制严重排斥反应。直接因排斥反应导致的再次移植率较低（1.6%）。无论是早期还是术后6至12个月，对类固醇的需求都有限。